Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Digitalis

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    19 result(s) found for: Digitalis. Displaying page 1 of 1.
    EudraCT Number: 2004-004864-54 Sponsor Protocol Number: BCBe/04/Neb-Car/082 Start Date*: 2005-09-12
    Sponsor Name:Berlin-Chemie Menarini
    Full Title: COMPARISON OF THE EFFECTS OF COMBINED RATE- AND RHYTHM-CONTROL TREATMENT WITH NEBIVOLOL AND ELECTRIC CARDIOVERSION TO RATE-CONTROL TREATMENT WITH NEBIVOLOL ALONE ON CLINICAL AND ECHOCARDIOGRAPHIC P...
    Medical condition: PATIENTS WITH HYPERTENSION AND LEFT-VENTRICULAR DYSFUNCTION INDUCED BY TACHYCARDIA
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-003075-12 Sponsor Protocol Number: 290478 Start Date*: Information not available in EudraCT
    Sponsor Name:Department Of Paediatric Cardiology
    Full Title: Effect of carvedilol on left ventricular systolic and diastolic function and the neurohormonal axis in patients with Duchenne muscular dystrophy and left ventricular dysfunction.
    Medical condition: Duchenne muscular dystrophy is an X-linked inherited disorder which primarily affects skeletal muscle through a mutation in dystrophin which maps to the long arm of the X chromosome (Xp21). Patient...
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-001384-11 Sponsor Protocol Number: captaf Start Date*: 2008-04-03
    Sponsor Name:
    Full Title: Catheter Ablation compared with Pharmacological Therapy for Atrial Fibrillation – the CAPTAF trial
    Medical condition: To study the effect of catheter ablation (using CE marked products) on the quality of life an in patients with atrial fibrillation depsite treatment with conevntional antiarrhythmic medical therapy...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10066664 Recurrent symptomatic atrial fibrillation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-004060-40 Sponsor Protocol Number: AGO15 Start Date*: 2008-03-13
    Sponsor Name:Studienzentrale AGO Austria
    Full Title: Phase II multicenter trial of the Austrian AGO of the combination of liposomal Doxorubicin (Myocet®) and Carboplatin in primary advanced or metastatic and recurrent endometrial cancer
    Medical condition: primary advanced or recurrent/metastatic endometrial cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2018-001518-13 Sponsor Protocol Number: 10407 Start Date*: 2018-11-12
    Sponsor Name:Maatschap Cardiologie Zwolle
    Full Title: Comparison between treatment with catheter ablation or anti-arrhythmic drugs (sotalol or combination of verapamil and flecainide) of patients with benign ventricular premature beats and ventricular...
    Medical condition: Premature ventricular beats, ventricular ectopy, ventricle tachycardia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-003482-68 Sponsor Protocol Number: BAY 63-2521/12934 Start Date*: 2008-11-26
    Sponsor Name:Bayer HealthCare AG
    Full Title: Randomized, double-blind, placebo-controlled, multi-centre, multi-national study to evaluate the efficacy and safety of oral BAY 63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg tid) in patients with symptom...
    Medical condition: Pulmonary Arterial Hypertension (PAH)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064911 Pulmonary arterial hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IE (Prematurely Ended) AT (Completed) ES (Completed) NL (Completed) FR (Completed) SE (Completed) GB (Completed) CZ (Completed) DK (Completed) BE (Completed) IT (Completed) PT (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2007-000072-16 Sponsor Protocol Number: BAY63-2521/11348 Start Date*: Information not available in EudraCT
    Sponsor Name:Bayer HealthCare AG
    Full Title: Randomized, double-blind, placebo-controlled, multi-centre, multi-national study to evaluate the efficacy and safety of oral BAY 63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg tid) in patients with Chronic...
    Medical condition: Chronic Thromboembolic Pulmonary Hypertension
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10037406 Pulmonary hypertension secondary LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IE (Prematurely Ended) GB (Completed) AT (Completed) ES (Completed) NL (Completed) FR (Completed) IT (Completed) BE (Completed) CZ (Completed) SK (Completed) PT (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2012-002104-40 Sponsor Protocol Number: BAY63-2521/16097 Start Date*: 2013-03-14
    Sponsor Name:Bayer HealthCare AG
    Full Title: An open-label phase IIIb study of riociguat in patients with in-operable CTEPH, or recurrent or persisting PH after surgical treatment who are not satisfactorily treated and cannot participate in ...
    Medical condition: Chronic Trombo Embolic Pulmonary Hypertention
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004855 10068740 CTEPH LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DE (Completed) PT (Completed) ES (Completed) BE (Completed) CZ (Completed) DK (Completed) NL (Completed) IT (Completed) AT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-001287-34 Sponsor Protocol Number: BAY1067197/16718 Start Date*: 2013-11-04
    Sponsor Name:Bayer HealthCare AG
    Full Title: A single blind, placebo controlled pilot study to explore the safety and tolerability of a single oral dose of 30 mg BAY 1067197 in patients with chronic heart failure on the background of preexist...
    Medical condition: Heart failure
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004849 10019279 Heart failure LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2015-002516-33 Sponsor Protocol Number: NCT01420393 Start Date*: 2015-09-03
    Sponsor Name:University of Ottawa Heart Institute
    Full Title: A Randomized Ablation-based atrial Fibrillation rhythm control versus rate control Trial in patients with heart failure and high burden Atrial Fibrillation
    Medical condition: The study is comparing two accepted treatment methods (rhythm control-Catheter ablation with or without anti-arrhythmic drug control of maintaining sinus rhythm versus rate controls with medical th...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-004225-10 Sponsor Protocol Number: 3001081 Start Date*: 2005-03-07
    Sponsor Name:Orion Pharma
    Full Title: Effects of peroral levosimendan in the prevention of further hospitalisations in patients with chronic heart failure. A randomised, double-blind, placebo-controlled, multi-centre, parallel-group study
    Medical condition: Cardiac Failure
    Disease: Version SOC Term Classification Code Term Level
    7.1 10007554 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) LT (Completed) LV (Completed) EE (Completed)
    Trial results: View results
    EudraCT Number: 2007-001994-27 Sponsor Protocol Number: 2006B180 Start Date*: 2007-09-03
    Sponsor Name:Academisch Medisch Centrum
    Full Title: The effect of beta-adrenergic receptor blockade on sympathetic activity and coagulation in patients with heart failure (BACH-F study)
    Medical condition: Congestive heart failure
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010684 Congestive heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-018863-40 Sponsor Protocol Number: BAY63-2521/15096 Start Date*: 2010-07-16
    Sponsor Name:Bayer HealthCare AG
    Full Title: An interaction study to evaluate changes in blood pressure following 1, 1.5, 2, and 2.5 mg riociguat tid (dose titration) compared to placebo treatment on the background of stable sildenafil pretre...
    Medical condition: Pulmonary arterial hypertension
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10064911 Pulmonary arterial hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) CZ (Prematurely Ended) PL (Prematurely Ended) AT (Completed) IT (Prematurely Ended) GB (Prematurely Ended) ES (Completed)
    Trial results: View results
    EudraCT Number: 2008-007455-26 Sponsor Protocol Number: GS-US-235-0101 Start Date*: 2010-01-21
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-ranging Study of Cicletanine in Subjects with Pulmonary Arterial Hypertension
    Medical condition: Pulmonary hypertension (PH) is a serious and life-threatening disease of the pulmonary vasculature, characterized by profound vasoconstriction and an abnormal proliferation of smooth muscle cells i...
    Disease: Version SOC Term Classification Code Term Level
    13.1 10038738 - Respiratory, thoracic and mediastinal disorders 10064911 Pulmonary arterial hypertension PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: AT (Prematurely Ended) DE (Prematurely Ended) BE (Prematurely Ended) GB (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-001633-40 Sponsor Protocol Number: ESRA Start Date*: 2022-03-07
    Sponsor Name:Thoraxklinik Heidelberg gGmbH
    Full Title: Efficacy and safety of riociguat (MK-4836) in incipient pulmonary vascular disease as an indicator for early pulmonary arterial Hypertension Doubleblind, randomized, multicentre, multinational, pla...
    Medical condition: early pulmonary vascular disease, defined as either a) mean pulmonary arterial pressure (mPAP) ≥25 mmHg with pulmonary vascular resistance (PVR) ≥2 to <3 WU and pulmonary arterial wedge pressure (P...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004866 10037455 Pulmonary vascular disorders NEC HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-001312-59 Sponsor Protocol Number: CRO1824 Start Date*: 2011-06-24
    Sponsor Name:Imperial College London
    Full Title: A double-blinded, randomized, crossover clinical study to assess the efficacy of Qutenza (capsaicin 8% patches) for the reduction of site pain caused by continuous subcutaneous infusion of Remoduli...
    Medical condition: Pulmonary arterial hypertension (PAH) is a rare life-threatening disease characterised by high blood pressure in the arteries to the lungs, rapidly evolving in a clinical syndrome of dyspnoea and f...
    Disease: Version SOC Term Classification Code Term Level
    13.1 10038738 - Respiratory, thoracic and mediastinal disorders 10037400 Pulmonary hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-005462-34 Sponsor Protocol Number: 202006RCT Start Date*: 2021-06-23
    Sponsor Name:Thoraxklinik Heidelberg gGmbH
    Full Title: An open-label, prospective, single centre study of the effects of Riociguat on RIght VEntricular size and function in Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension
    Medical condition: Symptomatic pulmonary arterial hypertension with a mean pulmonary artery pressure >20 mmHg and pulmonary vascular resistance ≥2 Wood Units, pulmonary arterial wedge pressure ≤15 mmHg (Group I / Nic...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004855 10037401 Pulmonary hypertensions HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-003014-28 Sponsor Protocol Number: FARM12JCXN Start Date*: 2017-10-30
    Sponsor Name:UMBERTO I - POLICLINICO DI ROMA
    Full Title: MULTICENTER RANDOMIZED STUDY ON THE EFFICACY OF IMMUNOSUPPRESSION IN PATIENTS WITH VIRUS-NEGATIVE INFLAMMATORY CARDIOMYOPATHY
    Medical condition: virus negative inflammatory cardiomyopathy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10007636 Cardiomyopathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-000490-40 Sponsor Protocol Number: S320.2.003 Start Date*: 2007-06-20
    Sponsor Name:Solvay Pharmaceuticals GmbH
    Full Title: Randomised, Double-Blind, Placebo-Controlled, Multi-Center, Sequential Cohort Study to Evaluate the Effect of SLV320 in Addition to Chronic Furosemide Treatment on Renal Function in Subjects with C...
    Medical condition: Renal Function in Subjects with Congestive Heart Failure and Impaired Renal Function who are on Chronic Furosemide Treatment
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010684 Congestive heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) CZ (Prematurely Ended) ES (Ongoing) DE (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 13 12:27:42 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA